Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06379087

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Prospective Phase II Study of Hypofractionated Radiotherapy Sequential Tislelizumab and Anlotinib in the Neoadjuvant and Adjuvant Therapy for Stage II-IIIA Non-Small Cell Lung Cancer

Sponsor: Ji Yongling

Conditions Non-Small Cell Lung Cancer

Interventions Anlotinib Hydrochloride Capsule Hypofractionated Radiotherapy Tislelizumab Injection

Updated 4 times since 2024 Last updated: Jul 6, 2025 Started: May 1, 2024 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Ji Yongling and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Aug 2025 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Aug 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ji Yongling

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China